Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
WITHDRAWN: Anticholinergics for urinary symptoms in multiple sclerosis.
Nicholas RS, Friede T, Hollis S, Young CA. Nicholas RS, et al. Among authors: young ca. Cochrane Database Syst Rev. 2015 Jun 5;2015(6):CD004193. doi: 10.1002/14651858.CD004193.pub3. Cochrane Database Syst Rev. 2015. PMID: 26043867 Free PMC article. Review.
Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C. Shakespeare DT, et al. Cochrane Database Syst Rev. 2001;(4):CD001332. doi: 10.1002/14651858.CD001332. Cochrane Database Syst Rev. 2001. PMID: 11687107 Updated. Review.
Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C. Shakespeare DT, et al. Cochrane Database Syst Rev. 2003;(4):CD001332. doi: 10.1002/14651858.CD001332. Cochrane Database Syst Rev. 2003. PMID: 14583932 Review.
Anticholinergics for urinary symptoms in multiple sclerosis.
Nicholas RS, Friede T, Hollis S, Young CA. Nicholas RS, et al. Among authors: young ca. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004193. doi: 10.1002/14651858.CD004193.pub2. Cochrane Database Syst Rev. 2009. PMID: 19160231 Updated. Review.
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S; MS-SMART Investigators. Chataway J, et al. Lancet Neurol. 2020 Mar;19(3):214-225. doi: 10.1016/S1474-4422(19)30485-5. Epub 2020 Jan 22. Lancet Neurol. 2020. PMID: 31981516 Free PMC article. Clinical Trial.
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis.
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J, Evangelou N, Scolding N, Rog D, Nicholas R, Marta M, Blain C, Young CA, Ford HL, Matthews PM. Dobson R, et al. Among authors: young ca. BMJ Open. 2021 Nov 25;11(11):e050176. doi: 10.1136/bmjopen-2021-050176. BMJ Open. 2021. PMID: 34824113 Free PMC article.
341 results